0	10	Expression	expression	NN
11	13	of	of	IN
14	19	c-fos	c-fos	NN
20	30	correlates	correlate	VBZ
31	35	with	with	IN
36	45	IFN-alpha	IFN-alpha	NNP
46	60	responsiveness	responsiveness	NN
61	63	in	in	IN
64	76	Philadelphia	Philadelphia	NNP
77	87	chromosome	chromosome	NN
88	96	positive	positive	JJ
97	104	chronic	chronic	JJ
105	116	myelogenous	myelogenous	JJ
117	125	leukemia	leukemia	NN
125	126	.	.	.

128	132	This	this	DT
133	138	study	study	NN
139	148	evaluates	evaluate	VBZ
149	150	(	(	(
150	151	i	i	LS
151	152	)	)	)
153	165	constitutive	constitutive	JJ
166	172	levels	level	NNS
173	175	of	of	IN
176	184	oncogene	oncogene	NN
185	188	and	and	CC
189	192	p53	p53	NN
193	204	transcripts	transcript	NNS
205	207	in	in	IN
208	215	chronic	chronic	JJ
216	221	phase	phase	NN
222	225	CML	CML	NNP
226	234	patients	patient	NNS
235	238	and	and	CC
239	240	(	(	(
240	242	ii	ii	LS
242	243	)	)	)
244	249	their	their	PRP$
250	261	modulations	modulation	NNS
262	272	subsequent	subsequent	JJ
273	275	to	to	TO
276	278	in	in	FW
279	283	vivo	vivo	FW
284	291	therapy	therapy	NN
292	296	with	with	IN
297	307	rIFN-alpha	rifn-alpha	NN
308	311	2c.	2c.	CD
312	322	Peripheral	peripheral	JJ
323	328	blood	blood	NN
329	340	mononuclear	mononuclear	JJ
341	346	cells	cell	NNS
347	348	(	(	(
348	352	pbmc	pbmc	NN
352	353	)	)	)
354	357	and	and	CC
358	362	bone	bone	NN
363	369	marrow	marrow	NN
370	375	cells	cell	NNS
376	378	of	of	IN
379	381	26	26	CD
382	390	patients	patient	NNS
391	395	were	be	VBD
396	404	examined	examine	VBN
405	408	for	for	IN
409	414	c-fos	c-fos	NN
414	415	,	,	,
416	421	c-myc	c-myc	NN
421	422	,	,	,
423	426	p53	p53	NN
427	430	and	and	CC
431	434	the	the	DT
435	441	hybrid	hybrid	NN
442	449	bcr/abl	bcr/abl	NN
450	454	mRNA	mrna	NN
455	461	levels	level	NNS
461	462	.	.	.

463	470	Results	result	NNS
471	480	indicated	indicate	VBD
481	485	that	that	IN
486	487	(	(	(
487	488	i	i	LS
488	489	)	)	)
490	502	constitutive	constitutive	JJ
503	508	c-fos	c-fos	NN
509	519	transcript	transcript	NN
520	526	levels	level	NNS
527	530	are	be	VBP
531	544	significantly	significantly	RB
545	551	higher	high	JJR
552	554	in	in	IN
555	563	patients	patient	NNS
564	576	subsequently	subsequently	RB
577	587	responding	respond	VBG
588	590	to	to	TO
591	600	IFN-alpha	IFN-alpha	NNP
601	608	therapy	therapy	NN
609	610	(	(	(
610	611	p	p	NN
612	613	<	<	SYM
614	618	0.01	0.01	CD
618	619	)	)	)
620	623	and	and	CC
624	634	positively	positively	RB
635	645	correlated	correlate	VBD
646	650	with	with	IN
651	654	the	the	DT
655	665	proportion	proportion	NN
666	668	of	of	IN
669	680	lymphocytes	lymphocyte	NNS
681	682	(	(	(
682	683	r	r	NN
684	685	=	=	SYM
686	692	0.6895	0.6895	CD
692	693	,	,	,
694	695	p	p	NN
696	697	<	<	SYM
698	702	0.01	0.01	CD
702	703	)	)	)
704	707	and	and	CC
708	718	negatively	negatively	RB
719	723	with	with	IN
724	727	the	the	DT
728	738	proportion	proportion	NN
739	741	of	of	IN
742	750	immature	immature	JJ
751	756	cells	cell	NNS
757	758	(	(	(
758	759	r	r	NN
760	761	=	=	SYM
762	768	-0.568	-0.568	CD
768	769	,	,	,
770	771	p	p	NN
772	773	<	<	SYM
774	778	0.01	0.01	CD
778	779	)	)	)
780	789	contained	contain	VBN
790	792	in	in	IN
793	796	the	the	DT
797	801	pbmc	pbmc	NN
802	814	preparations	preparation	NNS
815	821	tested	test	VBN
821	822	,	,	,
823	824	(	(	(
824	826	ii	ii	LS
826	827	)	)	)
828	840	constitutive	constitutive	JJ
841	845	mRNA	mrna	NN
846	852	levels	level	NNS
853	855	of	of	IN
856	859	the	the	DT
860	866	hybrid	hybrid	NN
867	874	bcr/abl	bcr/abl	NN
874	875	,	,	,
876	881	c-myc	c-myc	NN
882	885	and	and	CC
886	889	p53	p53	NN
890	893	are	be	VBP
894	904	positively	positively	RB
905	915	correlated	correlate	VBN
916	920	with	with	IN
921	925	each	each	DT
926	931	other	other	JJ
931	932	,	,	,
933	936	but	but	CC
937	943	failed	fail	VBD
944	946	to	to	TO
947	953	relate	relate	VB
954	956	to	to	TO
957	964	disease	disease	NN
965	975	parameters	parameter	NNS
975	976	,	,	,
977	980	and	and	CC
981	982	(	(	(
982	985	iii	iii	LS
985	986	)	)	)
987	992	acute	acute	JJ
993	996	and	and	CC
997	1004	chronic	chronic	JJ
1005	1007	in	in	FW
1008	1012	vivo	vivo	FW
1013	1021	exposure	exposure	NN
1022	1024	to	to	TO
1025	1034	IFN-alpha	IFN-alpha	NNP
1035	1037	is	be	VBZ
1038	1049	accompanied	accompany	VBN
1050	1052	by	by	IN
1053	1065	upregulation	upregulation	NN
1066	1068	of	of	IN
1069	1074	c-fos	c-fos	NN
1075	1078	and	and	CC
1079	1093	downregulation	downregulation	NN
1094	1096	of	of	IN
1097	1102	c-myc	c-myc	NN
1103	1107	mRNA	mrna	NN
1108	1114	levels	level	NNS
1115	1117	in	in	IN
1118	1127	responder	responder	NN
1128	1136	patients	patient	NNS
1136	1137	.	.	.